东宝生物(300239) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥108,075,675.55, representing a year-on-year increase of 17.32%[8] - Net profit attributable to shareholders of the listed company was ¥6,179,054.09, up 2.90% compared to the same period last year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥5,500,175.84, a slight increase of 0.83% year-on-year[8] - Basic earnings per share for the reporting period were ¥0.0134, an increase of 3.88% year-on-year[8] - The company achieved a revenue of CNY 339,104,382.18 in the first three quarters of 2019, representing a year-on-year growth of 5.22%[25] - Operating profit for the same period was CNY 27,576,557.83, an increase of 2.67% compared to the previous year[25] - The total profit amounted to CNY 30,073,895.18, reflecting a growth of 12.03% year-on-year[25] - The net profit attributable to shareholders reached CNY 25,872,173.47, marking a 13.55% increase from the previous year[25] - The total operating income for the year-to-date period was ¥339,104,382.18, up from ¥322,296,512.05, indicating a growth of approximately 5.2%[62] - The total operating costs for the year-to-date period were ¥314,894,718.74, compared to ¥296,253,938.21 in the previous year, which is an increase of about 6.3%[62] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,250,215,773.63, an increase of 4.29% compared to the end of the previous year[8] - Net assets attributable to shareholders of the listed company amounted to ¥982,713,675.24, reflecting a growth of 30.88% year-on-year[8] - Total current assets decreased to CNY 466.5 million from CNY 477.2 million, a decline of approximately 1.5%[46] - Total non-current assets increased to CNY 783.71 million from CNY 721.54 million, an increase of approximately 8.6%[46] - Total liabilities decreased to CNY 267.50 million from CNY 447.86 million, a decrease of approximately 40.2%[47] - Total equity increased to CNY 982.71 million from CNY 750.88 million, an increase of about 30.8%[48] - The company reported a total liabilities decrease to CNY 267,204,067.60 from CNY 447,188,265.71 year-over-year[53] - The total assets of the company reached CNY 1,255,289,411.45, compared to CNY 1,207,908,499.37 in the previous year[53] Cash Flow - The net cash flow from operating activities showed a significant decline, amounting to -¥55,624,350.37, a decrease of 405.16% compared to the previous year[8] - Cash flow from operating activities showed a net outflow of ¥55,624,350.37, contrasting with a net inflow of ¥18,228,225.75 in the same period last year[73] - Investment activities resulted in a net cash outflow of ¥133,876,970.61, compared to a smaller outflow of ¥25,829,582.16 in the previous year[73] - Financing activities generated a net cash inflow of ¥189,647,263.66, significantly higher than the previous year's inflow of ¥35,350,255.93[73] - The ending cash and cash equivalents balance was ¥67,295,696.78, down from ¥81,931,267.51 in the previous year[73] Research and Development - The company has established a strong focus on R&D, with 12 research labs dedicated to various aspects of collagen and gelatin applications, resulting in 3 new authorized invention patents in 2019[28] - The purification and separation project for bone collagen peptides has shown promising results, indicating that the isolated small peptides promote the proliferation and differentiation of osteoblasts[29] - The company has confirmed the experimental plan for the second animal trial in the study of the tumor-inhibiting mechanism of bone collagen peptides, with patents granted in both China and the US[30] - The electrospun gelatin fiber hemostatic material project is progressing, with the purification plant completed and product registration preparations underway, aiming for production by the end of the year[31] - The development of ultra-low endotoxin gelatin preparation technology is underway, targeting applications in absorbable hemostatic cotton and tissue engineering scaffolds[32] Market Expansion and Product Development - The company is actively pursuing market expansion in the health and beauty sectors, including the development of collagen-based skincare products[27] - The company has successfully developed a new product, "compound bone collagen," primarily used in the frozen prepared meat processing industry, and has obtained the necessary food production license[36] - The company is committed to high-quality development, focusing on the "medical, food, beauty, and health" sectors to enhance product value and meet market demands[35] - The company has initiated research on the high-tech applications of collagen protein in various fields, including biomedicine and food packaging[33] Financial Management - The company's financial expenses decreased by 77.92% to CNY 387,562.32, attributed to reduced bank loans[21] - The company reported a financial expense of -CNY 44,773.89, a significant improvement from CNY 675,494.83 in the previous period[55] - Financial expenses decreased significantly to -¥33,225.44 from ¥675,963.71, indicating improved financial management[59] - The company has implemented a clear and stable cash dividend policy, ensuring transparency and protecting shareholders' rights[39]